Key result
Baseline methylglyoxal predicts 5-year increases in IMT, PWV, and SBP in type 2 diabetes.
Why the study?
Plasma methylglyoxal levels as an independent risk factor predicting progression of diabetic macroangiopathy or microangiopathy in type 2 diabetes were unclear.
Does baseline plasma methylglyoxal level predict the progression of diabetic macroangiopathy or microangiopathy in type 2 diabetic patients?
Population
50 type 2 diabetic patients
Comparison
Baseline plasma levels of methylglyoxal vs 3-deoxyglucosone
Design
Cohort study
Follow-up
5 years
Authors
Loading...
Plasma MG may predict diabetic vascular progression; hypothesis-generating and should not yet change practice.
Cohort (n=50)
Does baseline plasma methylglyoxal level predict the progression of diabetic macroangiopathy or microangiopathy in type 2 diabetic patients?
Baseline plasma methylglyoxal levels independently predict the progression of intima-media thickening, arterial stiffness, and systolic blood pressure elevation over 5 years in type 2 diabetic patients.
Ogawa et al. (2010) conducted a cohort in Type 2 diabetes (n=50). Plasma level of methylglyoxal (MG) was evaluated on Percentage changes in IMT, SBP, ACR, PWV, and eGFR over 5 years. Baseline plasma methylglyoxal is an independent predictor of 5-year increases in intima-media thickness, pulse wave velocity, and systolic blood pressure in type 2 diabetic patients.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: